Malondialdehyde mediates oxidized LDL-induced coronary toxicity through the Akt-FGF2 pathway via DNA methylation

Journal of Biomedical Science

Volumn 21, Issue 1, 2014, Pages

  Yang, Tzu Ching ^a   Chen, Yi Jie ^a   Chang, Shwu Fen ^b   Chen, Chu Huang ^c,d,e   Chang, Po Yuan ^f   Lu, Shao Chun ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TEXAS HEART INSTITUTE   (United States)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

DNA methylation; Epigenetics; Gene expression; Lipid oxidation; Lipoproteins; Malondialdehyde (MDA); Signal transduction

Indexed keywords

ANTIBODY; DNA; FIBROBLAST GROWTH FACTOR 2; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN KINASE B;

ARTICLE; ATHEROSCLEROSIS; BIOSYNTHESIS; CELL SURVIVAL; CORONARY BLOOD VESSEL; CYTOLOGY; DNA METHYLATION; DRUG ANTAGONISM; DRUG EFFECT; ENDOTHELIUM CELL; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; OXIDATIVE STRESS; PATHOLOGY;

ANTIBODIES; ATHEROSCLEROSIS; CELL SURVIVAL; CORONARY VESSELS; DNA; DNA METHYLATION; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTOR 2; HUMANS; LIPOPROTEINS, LDL; MALONDIALDEHYDE; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84893170649     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-21-11     Document Type: Article

References (38)

1. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, Komatsu R, Matsuo T, Itabe H, Takano T, et al. Circulation 2001 103 1955 1960 10.1161/01.CIR.103.15.1955 11306523 (Pubitemid 32322222)
2. Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets. Lahoute C, Herbin O, Mallat Z, Tedgui A, Nat Rev Cardiol 2011 8 348 358 10.1038/nrcardio.2011.62 21502963
3. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, Vahabzadeh K, Hama S, Hough G, Kamranpour N, et al. J Lipid Res 2004 45 993 1007 10.1194/jlr.R400001-JLR200 15060092 (Pubitemid 38679495)
4. Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Shaw PX, Horkko S, Tsimikas S, Chang MK, Palinski W, Silverman GJ, Chen PP, Witztum JL, Arterioscler Thromb Vasc Biol 2001 21 1333 1339 10.1161/hq0801.093587 11498462 (Pubitemid 34219841)
5. Markers of oxidative stress in ICU clinical settings: present and future. Grune T, Berger MM, Curr Opin Clin Nutr Metab Care 2007 10 712 717 10.1097/MCO.0b013e3282f0c97c 18089952 (Pubitemid 350293771)
6. Malondialdehyde-acetaldehyde adduct is the dominant epitope after MDA modification of proteins in atherosclerosis. Duryee MJ, Klassen LW, Schaffert CS, Tuma DJ, Hunter CD, Garvin RP, Anderson DR, Thiele GM, Free Radic Biol Med 2010 49 1480 1486 10.1016/j.freeradbiomed.2010.08.001 20696236
7. Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression. Tsimikas S, Miyanohara A, Hartvigsen K, Merki E, Shaw PX, Chou MY, Pattison J, Torzewski M, Sollors J, Friedmann T, et al. J Am Coll Cardiol 2011 58 1715 1727 10.1016/j.jacc.2011.07.017 21982317
8. The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study. Lopes-Virella MF, Hunt KJ, Baker NL, Virella G, Moritz T, Atherosclerosis 2012 224 526 531 10.1016/j.atherosclerosis.2012.08.006 22963984
9. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. Liao JK, Shin WS, Lee WY, Clark SL, J Biol Chem 1995 270 319 324 10.1074/jbc.270.1.319 7529227
10. Regulation of G-protein alpha i2 subunit expression by oxidized low-density lipoprotein. Liao JK, Clark SL, J Clin Invest 1995 95 1457 1463 10.1172/JCI117816 7706449
11. Oxidized low-density lipoprotein downregulates endothelial basic fibroblast growth factor through a pertussis toxin-sensitive G-protein pathway: mediator role of platelet-activating factor-like phospholipids. Chang PY, Luo S, Jiang T, Lee YT, Lu SC, Henry PD, Chen CH, Circulation 2001 104 588 593 10.1161/hc3101.092213 11479258 (Pubitemid 32738130)
12. Oxidized low-density lipoproteins inhibit endothelial cell proliferation by suppressing basic fibroblast growth factor expression. Chen CH, Jiang W, Via DP, Luo S, Li TR, Lee YT, Henry PD, Circulation 2000 101 171 177 10.1161/01.CIR.101.2.171 10637205 (Pubitemid 30044257)
13. Inhibitory effects of hypercholesterolemia and ox-LDL on angiogenesis-like endothelial growth in rabbit aortic explants. Essential role of basic fibroblast growth factor. Chen CH, Cartwright J Jr, Li Z, Lou S, Nguyen HH, Gotto AM Jr, Henry PD, Arterioscler Thromb Vasc Biol 1997 17 1303 1312 10.1161/01.ATV.17.7.1303 9261260 (Pubitemid 27329853)
14. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. Seghezzi G, Patel S, Ren CJ, Gualandris A, Pintucci G, Robbins ES, Shapiro RL, Galloway AC, Rifkin DB, Mignatti P, J Cell Biol 1998 141 1659 1673 10.1083/jcb.141.7.1659 9647657 (Pubitemid 28309179)
15. Basic fibroblast growth factor and heparin influence coronary arteriolar tone by causing endothelium-dependent dilation. Tiefenbacher CP, Chilian WM, Cardiovasc Res 1997 34 411 417 10.1016/S0008-6363(97)00029-1 9205556 (Pubitemid 27241587)
16. Homocysteine inhibits arterial endothelial cell growth through transcriptional downregulation of fibroblast growth factor-2 involving G protein and DNA methylation. Chang PY, Lu SC, Lee CM, Chen YJ, Dugan TA, Huang WH, Chang SF, Liao WS, Chen CH, Lee YT, Circ Res 2008 102 933 941 10.1161/CIRCRESAHA.108.171082 18309099 (Pubitemid 351591555)
17. Isolation, characterization, and functional assessment of oxidatively modified subfractions of circulating low-density lipoproteins. Yang CY, Raya JL, Chen HH, Chen CH, Abe Y, Pownall HJ, Taylor AA, Smith CV, Arterioscler Thromb Vasc Biol 2003 23 1083 1090 10.1161/01.ATV.0000071350.78872.C4 12689919 (Pubitemid 36713565)
18. Functional characterization of the human basic fibroblast growth factor gene promoter. Shibata F, Baird A, Florkiewicz RZ, Growth Factors 1991 4 277 287 10.3109/08977199109043913 1764264
19. CpG-rich islands and the function of DNA methylation. Bird AP, Nature 1986 321 209 213 10.1038/321209a0 2423876 (Pubitemid 16016411)
20. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Takai D, Jones PA, Proc Natl Acad Sci U S A 2002 99 3740 3745 10.1073/pnas.052410099 11891299 (Pubitemid 34252176)
21. Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation. Chang PY, Lu SC, Su TC, Chou SF, Huang WH, Morrisett JD, Chen CH, Liau CS, Lee YT, J Lipid Res 2004 45 2116 2122 10.1194/jlr.M400229- JLR200 15314101 (Pubitemid 40990907)
22. Fibroblast growth factors as angiogenesis factors: new insights into their mechanism of action. Klein S, Roghani M, Rifkin DB, EXS 1997 79 159 192 9002232
23. Malondialdehyde-modified LDL as a marker of acute coronary syndromes. Holvoet P, Collen D, Van de Werf F, JAMA 1999 281 1718 1721 10.1001/jama.281.18. 1718 10328072 (Pubitemid 29226482)
24. Regulation of bFGF gene expression and subcellular distribution of bFGF protein in adrenal medullary cells. Stachowiak MK, Moffett J, Joy A, Puchacz E, Florkiewicz R, Stachowiak EK, J Cell Biol 1994 127 203 223 10.1083/jcb.127.1.203 7929563 (Pubitemid 24307668)
25. Promoter regions involved in density-dependent regulation of basic fibroblast growth factor gene expression in human astrocytic cells. Moffett J, Kratz E, Florkiewicz R, Stachowiak MK, Proc Natl Acad Sci U S A 1996 93 2470 2475 10.1073/pnas.93.6.2470 8637898 (Pubitemid 26104373)
26. Electronegative LDL circulating in smokers impairs endothelial progenitor cell differentiation by inhibiting Akt phosphorylation via LOX-1. Tang D, Lu J, Walterscheid JP, Chen HH, Engler DA, Sawamura T, Chang PY, Safi HJ, Yang CY, Chen CH, J Lipid Res 2008 49 33 47 10.1194/jlr.M700305-JLR200 17909223
27. Aspirin protects human coronary artery endothelial cells against atherogenic electronegative LDL via an epigenetic mechanism: a novel cytoprotective role of aspirin in acute myocardial infarction. Chang PY, Chen YJ, Chang FH, Lu J, Huang WH, Yang TC, Lee YT, Chang SF, Lu SC, Chen CH, Cardiovasc Res 2013 99 137 145 23519265
28. Epigenetic modifications in cardiovascular disease. Lorenzen JM, Martino F, Thum T, Basic Res Cardiol 2012 107 245 22234702
29. Genome-wide DNA methylation in human heart failure. Movassagh M, Vujic A, Foo R, Epigenomics 2011 3 103 109 10.2217/epi.10.70 22126157
30. Epigenetic modifications: basic mechanisms and role in cardiovascular disease. Handy DE, Castro R, Loscalzo J, Circulation 2011 123 2145 2156 10.1161/CIRCULATIONAHA.110.956839 21576679
31. Prior exposure to oxidized low-density lipoprotein limits apoptosis in subsequent generations of endothelial cells by altering promoter methylation. Mitra S, Khaidakov M, Lu J, Ayyadevara S, Szwedo J, Wang XW, Chen C, Khaidakov S, Kasula SR, Stone A, et al. Am J Physiol Heart Circ Physiol 2011 301 506 H513 10.1152/ajpheart.00252.2011 21602467
32. Different effects of homocysteine and oxidized low density lipoprotein on methylation status in the promoter region of the estrogen receptor alpha gene. Huang Y, Peng K, Su J, Huang Y, Xu Y, Wang S, Acta Biochim Biophys Sin (Shanghai) 2007 39 19 26 17213955 (Pubitemid 46115033)
33. OxLDL up-regulates microRNA-29b, leading to epigenetic modifications of MMP-2/MMP-9 genes: a novel mechanism for cardiovascular diseases. Chen KC, Wang YS, Hu CY, Chang WC, Liao YC, Dai CY, Juo SH, FASEB J 2011 25 1718 1728 10.1096/fj.10-174904 21266537
34. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Santini V, Kantarjian HM, Issa JP, Ann Intern Med 2001 134 573 586 10.7326/0003-4819-134-7-200104030-00011 11281740 (Pubitemid 32245319)
35. Downstream effects on human low density lipoprotein of homocysteine exported from endothelial cells in an in vitro system. Nakano E, Taiwo FA, Nugent D, Griffiths HR, Aldred S, Paisi M, Kwok M, Bhatt P, Hill MH, Moat S, Powers HJ, J Lipid Res 2005 46 484 493 15576841 (Pubitemid 43109785)
36. Redox-sensitive regulation of lox-1 gene expression in vascular endothelium. Nagase M, Ando K, Nagase T, Kaname S, Sawamura T, Fujita T, Biochem Biophys Res Commun 2001 281 720 725 10.1006/bbrc.2001.4374 11237717 (Pubitemid 32917860)
37. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Nishi K, Itabe H, Uno M, Kitazato KT, Horiguchi H, Shinno K, Nagahiro S, Arterioscler Thromb Vasc Biol 2002 22 1649 1654 10.1161/01.ATV. 0000033829.14012.18 12377744
38. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, Witztum JL, Berger PB, N Engl J Med 2005 353 46 57 10.1056/NEJMoa043175 16000355 (Pubitemid 41007806)